AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01358448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Monitoring plus Family-based Behavioral Counseling
Description: Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
Study NCT02246829 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravitreal injection
Description: 2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
Study NCT01896115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise DBS settings
Description: Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
Study NCT02954575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Study NCT06027775 — intervention group
Intervention type: DRUG
Intervention: Targeted agent
Description: The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
Study NCT02809274 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: • Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
Study NCT01498913 — intervention group
Intervention type: DRUG
Intervention: repaglinide
Description: Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
Study NCT00275496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Dissection
Description: Subject has wide excision and sentinel lymph node dissection for primary melanoma.
Study NCT00275496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Lymph Node Dissection
Description: Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
Study NCT00275496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Excision
Description: Subject has wide excision only for primary melanoma.
Study NCT02343575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 1.~Start:~VPA PO/NGT 500 mg BID~2.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS
Study NCT04249193 — intervention group
Intervention type: OTHER
Intervention: Transfusion
Description: pRBC and non-pRBC transfusions
Study NCT04576221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stacked breathing exercise
Description: • Breath stacking was done using a bag which is a simple device used to give artificial breaths..~* It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~* If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal.
Study NCT04576221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV by CPAP mask
Description: provides pressurized air through a mask to help push air into your lungs and help you breathe
Study NCT02186171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection once a month.
Study NCT02186171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month.
Study NCT01703221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
Study NCT01703221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
Study NCT01703221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
Study NCT01703221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 50 mg tablet administered orally once daily
Study NCT01703221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Placebo to omarigliptin 25 mg capsule administered orally once weekly
Study NCT01703221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Placebo to omarigliptin 25 mg capsule administered orally once weekly
Study NCT01703221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to sitagliptin
Description: Placebo to sitagliptin 50 mg tablet administered orally once daily
Study NCT02343575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500 mg matched to VPA BID PO/NGT
Study NCT02343575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Haloperidol
Description: Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
Study NCT02343575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
Study NCT03824938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 650mg Oral Capsule
Description: A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
Study NCT01703221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Placebo to sitagliptin 50 mg tablet administered orally once daily
Study NCT00954135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozolo+cyclophosphamide
Description: Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
Study NCT00954135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozolo+sorafenib+cyclophosphamide
Description: Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months
Study NCT00829283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One pill daily
Study NCT00829283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine/Orlistat
Description: Sibutramine 15 mg daily or Orlistat 120mg TID
Study NCT01444391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tube placement (Acclarent iontophoresis device)
Description: Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
Study NCT02587247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF2 antibody/68Ga-IMP-288
Description: TF2 antibody coupled with 68Ga-IMP-288
Study NCT01652911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sernova Cell Pouch
Description: The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
Study NCT03824938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Tablet 650mg
Description: A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
Study NCT03824938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
Study NCT02576834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention
Description: 10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
Study NCT01934543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
Study NCT01934543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
Study NCT02586883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bronchial ddp test
Description: bronchial ddp test during endoscopy, nasal smear, bronchial smear
Study NCT02586883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bronchial ddp test
Description: bronchial ddp test during endoscopy, nasal smear, bronchial smear
Study NCT02821676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction
Description: 30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
Study NCT00536861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity
Study NCT03211806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior
Description: Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
Study NCT03211806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bluetooth-enabled activity monitor
Description: Monitoring activity using a Bluetooth-enabled activity monitor
Study NCT03211806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bluetooth-enabled activity monitor
Description: Monitoring activity using a Bluetooth-enabled activity monitor
Study NCT01039012 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tai Chi
Description: Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
Study NCT01039012 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Participant follow the standard care recommended by their physician.
Study NCT02273739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
Study NCT03206905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty
Description: endoscopic, rather than surgical approach, to perform sleeve gastroplasty
Study NCT03206905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: nutritional/exercise counseling
Study NCT03206905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: nutritional/exercise counseling
Study NCT03641079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinjal peel extract containing cream
Description: Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
Study NCT03589430 — intervention group
Intervention type: OTHER
Intervention: Laboratory investigations ( protein C, protein S , antithrombin III)
Description: laboratory investigations ( protein C , protein S , antithrombin)
Study NCT01786018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Study NCT01786018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study NCT01786018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabin
Study NCT01786018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant (HCT)
Description: Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10\^7 CD3 cells/kg recipient weight and cryopreserved.
Study NCT01786018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cytoreduction
Description: Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
Study NCT01786018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression
Description: Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
Study NCT01786018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below.
Study NCT01786018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
Study NCT01786018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: (FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
Study NCT01786018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection and infusions of Donor PBSC
Description: Collection and infusions of Donor PBSC
Study NCT02624700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm A: Pemetrexed
Description: Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
Study NCT02624700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm A: Sorafenib
Description: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
Study NCT02624700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm B: Pemetrexed
Description: Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
Study NCT02624700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm B: Sorafenib
Description: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
Study NCT01707875 — intervention group
Intervention type: OTHER
Intervention: fetal brain neurosonography
Description: fetal brain neurosonography according to the ISUG guidelines
Study NCT04685603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
Study NCT03644797 — intervention group
Intervention type: GENETIC
Intervention: Exome sequencing
Description: Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
Study NCT03863496 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scoliosis surgery
Description: All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
Study NCT01771094 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Effect of sweetness of the beverage in thirst sensation
Description: Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
Study NCT01771094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of sweetness of the beverage in thirst sensation
Description: Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
Study NCT00649298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haemodialysis
Description: Comparison of different weekly duration of haemodialysis treatment
Study NCT00649298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: haemodialysis
Description: Comparison of different weekly duration of haemodialysis treatment
Study NCT03364998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Damoctocog (Jivi, BAY94-9027)
Description: 60 international units (IU)/kg, given as a 10 minute injection, 1 dose
Study NCT03364998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elocta
Description: 60 IU/kg, given as a 10 minute injection, 1 dose
Study NCT03312010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator HF
Description: A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
Study NCT03312010 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal Cord Stimulator Sham
Description: A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
Study NCT02522481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
Study NCT02046135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Study NCT02046135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Study NCT00136604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib-MenAC
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
Study NCT02094846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice messages
Description: Voice messages reinforced with self-efficacy
Study NCT01717846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 or Orencia treated group
Description: Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
Study NCT01717846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group 2 (DMARDS treated group)
Description: Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
Study NCT01691729 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ostomy accessory
Description: Wearing each of the devices for 10 days each
Study NCT01381523 — intervention group
Intervention type: DRUG
Intervention: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)
Description: Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data